Opportunity Overview
Germany – Pharmaceutical products – Open house drug discount agreements for the active ingredient natalizumab, i.v. dosage form, ATC L04AG03
Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | Health |
|---|---|
| Country | Germany |
| Category | Pharmaceuticals |
| Published | April 11, 2025 |
| Procurement stage | Active solicitation |
| Closed | March 31, 2027 |
| Status | Closed — no longer accepting responses |
| Translation | Translated from German by GlobalGov’s translation pipeline |
| Official source | View original notice |
| Last verified | August 10, 2026 |
Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.
Browse Similar Open Opportunities in Germany
Germany – Pharmaceutical products – OpenHouse-Verfahren Diverse Arzneimittelwirkstoffe ab 01.10.2025
See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Get a free Germany Pharmaceuticals intelligence report in your inbox
A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.